Are good patient and embryo characteristics protective against the negative effect of elevated progesterone level on the day of oocyte maturation? Micah.

Slides:

Advertisements

Similar presentations

Lisa Marii Cookingham, M. D. , Rachel P. Goossen, B. A. , Amy E. T

Advertisements

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis

Elevated serum progesterone level on the day of human chorionic gonadotropin administration does not adversely affect implantation rates after intracytoplasmic.

Nicole Banks, M. D. , George Patounakis, M. D. , Ph. D

Does elevated progesterone on day of oocyte maturation play a role in the racial disparities in IVF outcomes? Micah J. Hill, G. Donald Royster, Mansi.

A GnRH agonist and exogenous hormone stimulation protocol has a higher live-birth rate than a natural endogenous hormone protocol for frozen-thawed blastocyst-stage.

Is the effect of premature elevated progesterone augmented by human chorionic gonadotropin versus gonadotropin-releasing hormone agonist trigger? Matthew.

Human chorionic gonadotropin administration does not increase plasma androgen levels in patients undergoing controlled ovarian hyperstimulation Renato.

Impact of endogenous luteinizing hormone serum levels on progesterone elevation on the day of human chorionic gonadotropin administration Jean-noêl Hugues,

Ovarian reserve and subsequent assisted reproduction outcomes after methotrexate therapy for ectopic pregnancy or pregnancy of unknown location Micah.

Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor.

Impact of final oocyte maturation using gonadotropin-releasing hormone agonist triggering and different luteal support protocols on endometrial gene expression

Trophectoderm grade predicts outcomes of single-blastocyst transfers

Cem Atabekoglu, M. D. , Murat Sonmezer, M. D. , Sinan Özkavukcu, M. D

Factors associated with birth outcomes from cryopreserved blastocysts: experience from 4,597 autologous transfers of 7,597 cryopreserved blastocysts

Reproductive BioMedicine Online

Cutoff value of human chorionic gonadotropin in relation to the number of methotrexate cycles in the successful treatment of ectopic pregnancy Ewa Nowak-Markwitz,

Dramatic declines in implantation and pregnancy rates in patients who undergo repeated cycles of in vitro fertilization with blastocyst transfer after.

Antral follicle count as a predictor of ovarian responsiveness in women with endometriomas or with a history of surgery for endometriomas Laura Benaglia,

Iris G. Insogna, M. D. , Malinda S. Lee, M. D. , M. B. A. , Rebecca M

Grant D.E. McWilliams, D.O., John L. Frattarelli, M.D.

Effect of prolonged gonadotropin-releasing hormone agonist therapy on the outcome of in vitro fertilization-embryo transfer in patients with endometriosis

Subtle progesterone rise on the day of human chorionic gonadotropin administration is associated with lower live birth rates in women undergoing assisted.

Association of a single dose of gonadotropin-releasing hormone antagonist with nitric oxide and embryo quality in in vitro fertilization cycles Tsung-Hsien.

Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response Frank.

Progesterone luteal support after ovulation induction and intrauterine insemination: a systematic review and meta-analysis Micah J. Hill, D.O., Brian.

Matthew T. Connell, D. O. , Jennifer M. Szatkowski, B. S

Influences on endometrial development during intrauterine insemination: clinical experience of 2,929 patients with unexplained infertility Erin Foran.

Lisa Marii Cookingham, M. D. , Rachel P. Goossen, B. A. , Amy E. T

Robert F. Casper, M.D. Fertility and Sterility

Association of the very early rise of human chorionic gonadotropin with adverse outcomes in singleton pregnancies after in vitro fertilization Christopher.

Microdose flare protocol with interrupted follicle stimulating hormone and added androgen for poor responders—an observational pilot study Frederic Mitri,

Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose.

Revisiting the progesterone to oocyte ratio

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis

David E. Reichman, M.D., Dan Goldschlag, M.D., Zev Rosenwaks, M.D.

Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic.

Are intracytoplasmic sperm injection and high serum estradiol compounding risk factors for adverse obstetric outcomes in assisted reproductive technology?

Freeze-only versus fresh embryo transfer in a multicenter matched cohort study: contribution of progesterone and maternal age to success rates Ange Wang,

From partner's desk to iPad

Comparison of antimüllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis.

Does a frozen embryo transfer ameliorate the effect of elevated progesterone seen in fresh transfer cycles? Mae Wu Healy, D.O., George Patounakis, M.D.,

Quantitative grading of a human blastocyst: optimal inner cell mass size and shape Kevin S Richter, Ph.D., Dee C Harris, M.T., Said T Daneshmand, M.D.,

Age-specific probability of live birth with oocyte cryopreservation: an individual patient data meta-analysis Aylin Pelin Cil, M.D., Heejung Bang, Ph.D.,

Progesterone luteal support after ovulation induction and intrauterine insemination: an updated systematic review and meta-analysis Katherine A. Green,

Gonadotropin-releasing hormone antagonist use is associated with increased pregnancy rates in ovulation induction–intrauterine insemination to in vitro.

Clinical and endocrine response to the withdrawal of gonadotropin-releasing hormone agonists during prolonged coasting Basil Ho Yuen, M.B., Ch.B., Tuan-Anh.

Orhan Bukulmez, M. D. , Bruce R. Carr, M. D. , Kathleen M. Doody, M. D

Efficacy and safety of human chorionic gonadotropin for follicular phase stimulation in assisted reproduction: a systematic review and meta-analysis

Successful elective and medically indicated oocyte vitrification and warming for autologous in vitro fertilization, with predicted birth probabilities.

Assessment of luteinizing hormone level in the gonadotropin-releasing hormone antagonist protocol Georg Griesinger, M.D., Anja Dawson, M.D., Askan Schultze-Mosgau,

Birth weight is associated with inner cell mass grade of blastocysts

Bruce S Shapiro, M. D. , Kevin S Richter, Ph. D. , Dee C Harris, M. T

Effects of growth hormone and insulin-like growth factor 1 on progesterone production in human luteinized granulosa cells Toshiaki Taketani, M.D., Yoshiaki.

Predictive value of maternal serum human chorionic gonadotropin levels in pregnancies achieved by in vitro fertilization with single cleavage and single.

Absence of corpus luteum rescue by chorionic gonadotropin in women immunized with a contraceptive vaccine Rahul Pal, Ph.D., Om Singh, Ph.D. Fertility.

Hourly human chorionic gonadotropin secretion profiles during the peri-implantation period of successful pregnancies Pete N. Lohstroh, Ph.D, James W.

David H. Barad, M.D., M.S., Norbert Gleicher, M.D.

Experience with a patient-friendly, mandatory, single-blastocyst transfer policy: the power of one John M. Csokmay, M.D., Micah J. Hill, D.O., Rebecca.

Lower levels of inhibin A and pro-αC during the luteal phase after triggering oocyte maturation with a gonadotropin-releasing hormone agonist versus human.

First live birth after ovarian stimulation using a chimeric long-acting human recombinant follicle-stimulating hormone (FSH) agonist (recFSH-CTP) for.

Evaluating the role of exogenous luteinizing hormone in poor responders undergoing in vitro fertilization with gonadotropin-releasing hormone antagonists

Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian.

Conversion from assisted reproductive technology to intrauterine insemination in low responders: Is it advantageous? John M. Norian, M.D., Eric D. Levens,

A novel “delayed start” protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders Hakan Cakmak, M.D., Nam D. Tran,

Use of recombinant human chorionic gonadotropin in ovulation induction

A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for.

Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing.

In vitro viability and secretory capacity of human luteinized granulosa cells after gonadotropin-releasing hormone agonist trigger of oocyte maturation

The use of recombinant luteinizing hormone in patients undergoing assisted reproductive techniques with advanced reproductive age: a systematic review.

Presentation transcript:

Are good patient and embryo characteristics protective against the negative effect of elevated progesterone level on the day of oocyte maturation? Micah J. Hill, D.O., Greene Donald Royster, M.D., Mae Wu Healy, D.O., Kevin S. Richter, Ph.D., Gary Levy, M.D., Alan H. DeCherney, M.D., Eric D. Levens, M.D., Geeta Suthar, B.S.M.T., C.L.C.P., Eric Widra, M.D., Michael J. Levy, M.D. Fertility and Sterility Volume 103, Issue 6, Pages 1477-1484.e5 (June 2015) DOI: 10.1016/j.fertnstert.2015.02.038 Copyright © 2015 Terms and Conditions

Figure 1 Graphic representation of the effect of serum P values on implantation and live birth in cleavage and blastocyst embryo transfers. Progesterone values (ng/ml) are plotted on the x-axis, and implantation (A and B) and live birth (C and D) are on the y-axis. Actual implantation (A) and live birth (C) are shown per serum P value. Linear trend lines for implantation (B) and live birth (D) are shown per serum P value. hCG = human chorionic gonadotropin; P = progesterone. Fertility and Sterility 2015 103, 1477-1484.e5DOI: (10.1016/j.fertnstert.2015.02.038) Copyright © 2015 Terms and Conditions

Figure 2 Graphic representation of the effect of serum P values on implantation and live birth in good blastocyst and fair or poor blastocyst embryo transfers. Progesterone values (ng/ml) are plotted on the x-axis, and implantation (A and B) and live birth (C and D) are indicated on the y-axis. Actual implantation (A) and live birth (C) are shown per serum P value. Linear trend lines for implantation (B) and live birth (D) are shown per serum P value. hCG = human chorionic gonadotropin; P = progesterone. Fertility and Sterility 2015 103, 1477-1484.e5DOI: (10.1016/j.fertnstert.2015.02.038) Copyright © 2015 Terms and Conditions

Figure 3 Graphic representation of the effect of serum P values on implantation and live birth based on ovarian response. Progesterone values (ng/ml) are plotted on the x-axis, and implantation (A and B) and live birth (C and D) are indicated on the y-axis. Actual implantation (A) and live birth (C) are shown per serum P value. Linear trend lines for implantation (B) and live birth (D) are shown per serum P value. hCG = human chorionic gonadotropin; P = progesterone. Fertility and Sterility 2015 103, 1477-1484.e5DOI: (10.1016/j.fertnstert.2015.02.038) Copyright © 2015 Terms and Conditions

Supplemental Figure 1 Distribution of patients across ranges of serum P levels (ng/ml) on the day of hCG administration. hCG = human chorionic gonadotropin. Fertility and Sterility 2015 103, 1477-1484.e5DOI: (10.1016/j.fertnstert.2015.02.038) Copyright © 2015 Terms and Conditions

Supplemental Figure 2 Patient age, total medication dosage, and serum estradiol and progesterone concentrations at the point of trigger were complexly interrelated, as illustrated in this figure, which indicates statistically significant associations, along with regression (B) and correlation (r) coefficients. IU = international unit. Fertility and Sterility 2015 103, 1477-1484.e5DOI: (10.1016/j.fertnstert.2015.02.038) Copyright © 2015 Terms and Conditions

Supplemental Figure 3 Graphic representation of the effect of serum P values on implantation and live birth in good-cleavage and fair- or poor-cleavage embryo transfers. Progesterone values (ng/ml) are plotted on the x-axis, and implantation (A and B) and live birth (C and D) are indicated on the y-axis. Actual implantation (A) and live birth (C) are shown per serum P value. Linear trend lines for implantation (B) and live birth (D) are shown per serum P value. hCG = human chorionic gonadotropin; P = progesterone. Fertility and Sterility 2015 103, 1477-1484.e5DOI: (10.1016/j.fertnstert.2015.02.038) Copyright © 2015 Terms and Conditions

Supplemental Figure 4 Graphic representation of the effect of serum P values on implantation and live birth, based on patient age. Progesterone values (ng/ml) are plotted on the x-axis, and implantation (A and B) and live birth (C and D) are indicated on the y-axis. Actual implantation (A) and live birth (C) are shown per serum P value. Linear trend lines for implantation (B) and live birth (D) are shown per serum P value. The color-coded range values indicate patient age groups, in years. hCG = human chorionic gonadotropin; P = progesterone. Fertility and Sterility 2015 103, 1477-1484.e5DOI: (10.1016/j.fertnstert.2015.02.038) Copyright © 2015 Terms and Conditions

Supplemental Figure 5 Graphic representation of the effect of serum P values on implantation and live birth based on GnRH-agonist and GnRH-antagonist protocols. Progesterone values (ng/ml) are plotted on the x-axis, and implantation (A and B) and live birth (C and D) are indicated on the y-axis. Actual implantation (A) and live birth (C) are shown per serum P value. Linear trend lines for implantation (B) and live birth (D) are shown per serum P value. GnRH = gonadotropin releasing hormone; hCG = human chorionic gonadotropin; P = progesterone. Fertility and Sterility 2015 103, 1477-1484.e5DOI: (10.1016/j.fertnstert.2015.02.038) Copyright © 2015 Terms and Conditions